Nucleai announces strategic collaboration with Mayo Clinic BioPharma Diagnostics

Our portfolio company, Nucleai,  is pleased to announce a strategic collaboration with Mayo Clinic BioPharma Diagnostics to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice.

This collaboration combines Nucleai’s AI-powered spatial biology technology with Mayo’s longitudinally annotated, multi-modal data sets, world-class lab services, and clinical diagnostic footprint.

Access their full press release here